16 September 2026 editorial review · Trial
Fr1da: General-population infant/child islet-autoantibody screening (Bavaria): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: A–H
Outcome: Separated registered primary autoantibody outcome from secondary DKA/stress outcomes and qualified causal language; JAMA cohort denominator62 and2DKA checked.
Registry: NCT04039945. Registered endpoint checked: presence of multiple islet autoantibodies (up to 3 years). Eligibility check: Registry age 2 Years to 10 Years; substantive diagnosis/stage, device and other inclusion restrictions were compared with the public eligibility summary. The registry remains the source for full exclusions. Accessible primary literature: Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany.. Limits: Primary abstract findings were available; supplementary tables and full adverse-event adjudication were not comprehensively re-reviewed. Registry eligibility is not a claim of current site availability.